million and THB 180.38 million respectively, equivalent to a 43.52% decrease. Cost of goods sold to sales revenue ratio edged down slightly from 32.48% to 32.36% because of the changing sales mix that each

Interest Coverage ratio (EBITDA / Financing Cost) which edged up to 91x as of 30 September 2017. Debt to Equity Ratio decreased to extremely low level due to repayment of debt owed to financial institutions

/ Financing Cost) which edged up to 120x as of 31 December 2017. Debt to Equity Ratio decreased to extremely low level. Please be informed accordingly. Yours sincerely, (Mr. Wachira Wudhikulprapan) Managing

, this risk was relatively low. Interest Coverage ratio (EBITDA / Financing Cost) edged up to 350x in this quarter from 61x yoy while Debt to Equity Ratio maintained at extremely low level. Please be

, progress made in China, Chinese Taipei, India, Malaysia, the Philippines and Thailand was outlined by lead discussants. In Chinese Taipei, key developments include the creation of a CG ranking for individual

sales promotion expenses in the first quarter thanks to new products the Company introduced during the end of the past year. Consequently, sales expenses to sales revenue ratio edged up dramatically from

shows that the Company significantly reduced sales expenses from the previous year to suit the decrease in sales revenue. However, sales expenses to sales revenue ratio edged up a little from 34.69% to

. Cost of goods sold to sales revenue ratio edged up slightly from 30.22% to 30.65 % as a result of the changing sales mix that each product line contributed to total sales. Table 6: Cost of Goods Sold by

292.87 million and THB 263.02 million respectively. This is equivalent to a decrease of 11.35% compared to the same period last year. In addition, sales expenses to sales revenue ratio edged up a little

edged up a little from 35.04% to 37.80% as the Company incurred marketing expenses from new products launched in October. Table 7: Sales Expenses by Type of Expenses for the Three Months Period Ended 30